<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00896675</url>
  </required_header>
  <id_info>
    <org_study_id>VICC HN 0744</org_study_id>
    <secondary_id>P30CA068485</secondary_id>
    <secondary_id>VU-VICC-HN-0744</secondary_id>
    <secondary_id>VU-VICC-070359</secondary_id>
    <nct_id>NCT00896675</nct_id>
  </id_info>
  <brief_title>Blood Proteins in Predicting Treatment Benefit in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer</brief_title>
  <official_title>Proteomic Prediction of Clinical Benefit in HNSCC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of blood in the laboratory may help doctors learn more about
      cancer. It may also help doctors predict how well patients will respond to treatment.

      PURPOSE: This research study is looking at proteins in blood samples to predict treatment
      benefit in patients with recurrent and/or metastatic squamous cell head and neck cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To identify head and neck squamous cell cancer patients who will benefit from treatment
           with the EGFR inhibitors (i.e., erlotinib hydrochloride, gefitinib, and cetuximab) and
           VEGF inhibitor (i.e., bevacizumab), based on predictive proteomic profiles in patient
           blood samples.

      OUTLINE: This is a multicenter study.

      Blood samples are analyzed for proteomic profile to determine good and bad prognoses in
      patients treated with or without EGFR inhibitors and/or a VEGF inhibitor.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of patients who will benefit from treatment with EGFR and/or VEGF inhibitors based on serum proteomic profiles</measure>
    <time_frame>upon analysis of each patient tissue collection</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">352</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>patients treated with EGFR inhibitors and/or VEGF inhibitor</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>NOT treated with EGFR inhibitors and/or VEGF inhibitor</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>proteomic profiles</intervention_name>
    <description>blood samples analysis</description>
    <arm_group_label>patients treated with EGFR inhibitors and/or VEGF inhibitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>proteomic profiles</intervention_name>
    <description>blood samples analysis</description>
    <arm_group_label>NOT treated with EGFR inhibitors and/or VEGF inhibitor</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Head and Neck cancer patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of squamous cell head and neck cancer

               -  Recurrent and/or metastatic disease

          -  Meets 1 of the following criteria:

               -  Previously treated with EGFR inhibitors and/or VEGF inhibitor on 1 of the
                  following clinical trials, and has available blood samples:

                    -  A Phase I/II Study of Bevacizumab (rhu MAb VEGF) in Combination With OSI-774
                       for Patients With Recurrent or Metastatic Cancer of the Head and Neck

                    -  A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or
                       Both Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck

               -  Previously treated with cetuximab and has blood samples available from protocol
                  VU-VICC-HN-0356

               -  Previously treated with conventional chemotherapy and has blood samples available
                  from protocol VU-VICC-HN-0356

        PATIENT CHARACTERISTICS:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Murphy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center - Cool Springs</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center at Franklin</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6838</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>March 29, 2013</last_update_submitted>
  <last_update_submitted_qc>March 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Barbara Murphy, MD</investigator_full_name>
    <investigator_title>Professor of Medicine, Medical Oncologist</investigator_title>
  </responsible_party>
  <keyword>recurrent squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>metastatic squamous neck cancer with occult primary squamous cell carcinoma</keyword>
  <keyword>recurrent metastatic squamous neck cancer with occult primary</keyword>
  <keyword>recurrent squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>salivary gland squamous cell carcinoma</keyword>
  <keyword>stage IV salivary gland cancer</keyword>
  <keyword>recurrent salivary gland cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

